Gilead Sciences, Inc. $GILD Shares Sold by IFP Advisors Inc

IFP Advisors Inc decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 48.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,745 shares of the biopharmaceutical company’s stock after selling 6,376 shares during the quarter. IFP Advisors Inc’s holdings in Gilead Sciences were worth $748,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD raised its stake in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC acquired a new position in Gilead Sciences in the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in Gilead Sciences in the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. Citigroup upped their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.08.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,000 shares of company stock worth $7,632,100 in the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.9%

Shares of GILD stock opened at $118.21 on Tuesday. The stock has a market cap of $146.68 billion, a price-to-earnings ratio of 23.55, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a fifty-two week low of $84.34 and a fifty-two week high of $121.83. The firm’s 50 day moving average price is $114.72 and its two-hundred day moving average price is $110.30.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.